Since 1991, a range of important vaccines and medicines have been developed in Russia, including vaccines against COVID-19, treatments for HIV infection, drugs for treating tumors, and other therapeutic drugs.
Recent years have seen significant progress in modern vaccine development methods, relying on proven platforms and leading biotechnologies. During the COVID-19 pandemic, for example, Russia registered several vaccines developed using different technological platforms.
Among these treatments is Sputnik V , the world's first registered vaccine based on viral vector technology, developed by the Gamaleya National Research Center for Epidemiology and Microbiology. Also registered is EpiVacCorona , a peptide vaccine developed by the Vector State Research Center of Virology and Biotechnology, which is part of the Federal Service for Consumer Rights Protection and Human Welfare (Rospotrebnadzor).
Also among them is "CoveVac ," an inactivated vaccine based on the whole virus, developed by the Chumakov Federal Scientific Center for Research and Development of Immunological and Biological Products, of the Russian Academy of Sciences.
It is worth noting that in 2021 and 2022, Russia exported COVID-19 vaccines to various countries, including Argentina, Venezuela, India, Pakistan, Iran, and most African nations. Among the countries that imported Russian vaccines in 2021 were Mexico, the United Arab Emirates, Kazakhstan, and India.
Exports of the Sputnik V vaccine began in late 2020 with shipments sent to Belarus. Between 2020 and 2021, the Russian Direct Investment Fund entered into agreements with foreign companies to manufacture the vaccine outside of Russia, specifically in India, China, Brazil, Mexico, Egypt, Iran, Italy, South Korea, Argentina, Kazakhstan, Serbia, Turkey, Vietnam, and other countries.
In another area, the Gamaleya National Research Center for Epidemiology and Microbiology developed the first two Russian vaccines against Ebola hemorrhagic fever in 2015: GamiVac and GamiVac-Combi. In 2024, the 48th Central Research Institute of the Ministry of Defense developed and registered a chewable tablet vaccine for smallpox called TuVac, an inactivated vaccine that can be administered to previously unvaccinated individuals without risk of complications.
In the field of pharmaceuticals, in 2017 the company “Chemerar” developed the antiretroviral drug “Elpida” to treat HIV infection.
Russian pharmaceutical companies have also focused their efforts on finding treatments for cancerous diseases. In 2025, Nanolec received registration certification for Segardex, a vaccine against human papillomavirus types 6, 11, 16, and 18.
Among other drugs for treating certain types of cancer, Lonsorf, a combination of Trifluridine and Tipracil, was registered in Russia in 2025 for the treatment of colorectal and stomach cancer in patients over 18 years of age, in cases where other treatments have proven ineffective.
Avifavir: A drug based on the active ingredient "favipiravir," modified by Russia and approved as the first domestic antiviral drug for treating hospitalized COVID-19 patients.
Mir-19: A Russian inhalant drug based on "RNA interference" technology, which is characterized by precisely targeting parts of the viral genome to prevent its replication.
A monoclonal antibody-based drug originally developed to treat rheumatoid arthritis, and later successfully used to prevent a dangerous "cytokine storm" in respiratory patients.
immunotherapy treatment for kidney cancer, which Russia was the first to adopt and approve for use within its territory.
Neo OncoVac vaccine: A new drug, the clinical use of which for melanoma skin cancer patients has been announced. It is a personalized therapeutic vaccine based on messenger RNA technology.
Enteromex Vaccine: A revolutionary experimental anti-tumor vaccine that has entered clinical trials in colorectal cancer patients. It combines messenger RNA (mRNA) technology with the use of oncolytic viruses to stimulate the immune system. mRNA is a vital molecule in living cells that acts as an intermediary between DNA and protein synthesis.
An antimicrobial drug with an innovative mechanism of action was also developed. In 2024, the Gamaleya Center registered Phytocorthiazinone, a drug that does not kill bacteria, but rather deprives them of their virulence.
These are just a few examples of the significant advancements in vaccines and pharmaceuticals that Russia has witnessed since 1991. It's worth noting that many other innovative drugs are being developed at Russian state research centers, some of which are in their final stages. Drugs undergo a lengthy process, moving from initial research to various testing phases, culminating in official registration.
what is your opinion on this news ?do let us know in the comments on tha comment box
if you liked this news article please share on friends & family & don't forget to follow on website & social media
